Prostate cancer trials in Austria

In Austria 16 Also abroad 1480

16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Where
Graz, Linz, Wels
Age
18 years and over
People
1,310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00
Phase 3Taking people
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Where
Linz, Salzburg, Wels
Age
18 years and over
People
1,440 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00
Phase 1/2Taking people
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Where
Linz
Age
18 years and over
People
160 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00
Phase 3Taking people
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Where
Linz, Vienna
Age
18 years to 100 years
People
450 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00
Phase 3Taking people
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Where
Innsbruck, Linz, Sankt Pölten, Vienna
Age
18 years and over
People
750 worldwide
Run by
Amgen
See details and how to joinNCT07213674
Phase 3Taking people
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Where
Linz, Salzburg, Vienna
Age
18 years and over
People
670 worldwide
Run by
AstraZeneca
See details and how to joinNCT07611110
Phase 3Taking people
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
Where
Graz, Linz, Salzburg, Vienna
Age
18 years and over
People
1,330 worldwide
Run by
AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00
Phase 3Taking people
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Where
Graz, Innsbruck, Linz, Vienna
Age
18 years and over
People
700 worldwide
Run by
AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Graz, Vienna
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 3Taking people
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Where
Graz, Innsbruck, Linz, St. Poelten, Vienna
Age
18 years and over
People
297 worldwide
Run by
Amgen Inc.
See details and how to join2025-520555-89-00 · EU 2025-520555-89-00
Phase 2Taking people
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Where
Graz, Vienna
Age
18 years and over
People
37 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT04641247 · EU 2023-506618-29-00
No phaseTaking people
Combining High-frequency Micro-ultrasound and Multiparametric MRI Target Biopsy for Detecting Prostate Cancer
Where
Salzburg
Age
18 years to 99 years
People
400
Run by
Salzburger Landeskliniken
See details and how to joinNCT06579911
Phase 4Taking people
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Where
Linz, Vienna
Age
18 years to 100 years
People
700 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT05803941 · EU 2023-503208-94-00
No phaseTaking people
Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer
Where
Vienna
Age
18 years to 75 years
People
200
Run by
Medical University of Vienna
See details and how to joinNCT02971358
Phase 2Taking people
Neoadjuvant PSMA-RLT in Oligometastatic PCa
Where
Vienna
Age
18 years to 75 years
People
10
Run by
Medical University of Vienna
See details and how to joinNCT06259123
Phase 2Taking people
PSMA-RLT in Biochemically Recurrent PCa
Where
Vienna
Age
18 years to 80 years
People
20
Run by
Medical University of Vienna
See details and how to joinNCT06220188